To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Adamas' Gocovri for PD dyskinesia

Adamas Pharmaceuticals Inc. (NASDAQ:ADMS) gained $5.37 (38%) to $19.60 in after-hours

Read the full 117 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE